These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23635440)

  • 21. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy.
    Huo TI; Lin HC; Huang YH; Wu JC; Chiang JH; Lee PC; Lee SD
    Cancer; 2006 Jul; 107(1):141-8. PubMed ID: 16708358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of clinical staging systems in predicting survival of hepatocellular carcinoma patients receiving major or minor hepatectomy.
    Chen TW; Chu CM; Yu JC; Chen CJ; Chan DC; Liu YC; Hsieh CB
    Eur J Surg Oncol; 2007 May; 33(4):480-7. PubMed ID: 17129701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population.
    Chan SL; Mo FK; Johnson PJ; Liem GS; Chan TC; Poon MC; Ma BB; Leung TW; Lai PB; Chan AT; Mok TS; Yeo W
    J Gastroenterol Hepatol; 2011 Feb; 26(2):340-7. PubMed ID: 21261725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization.
    Memon K; Kulik LM; Lewandowski RJ; Wang E; Wang J; Ryu RK; Hickey R; Vouche M; Baker T; Ganger D; Gates VL; Habib A; Mulcahy MF; Salem R
    J Vasc Interv Radiol; 2014 Jul; 25(7):1056-66. PubMed ID: 24613269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatocellular carcinoma in uremic patients: is there evidence for an increased risk of mortality?
    Lee YH; Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Lee RC; Chiou YY; Huo TI
    J Gastroenterol Hepatol; 2013 Feb; 28(2):348-56. PubMed ID: 23190248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey.
    Huo TI; Lin HC; Hsia CY; Wu JC; Lee PC; Chi CW; Lee SD
    Am J Gastroenterol; 2007 Sep; 102(9):1920-30. PubMed ID: 17573792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort.
    Adhoute X; Pénaranda G; Raoul JL; Edeline J; Blanc JF; Pol B; Campanile M; Perrier H; Bayle O; Monnet O; Beaurain P; Muller C; Castellani P; Le Treut YP; Bronowicki JP; Bourlière M
    World J Gastroenterol; 2017 Apr; 23(14):2545-2555. PubMed ID: 28465639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre.
    Grieco A; Pompili M; Caminiti G; Miele L; Covino M; Alfei B; Rapaccini GL; Gasbarrini G
    Gut; 2005 Mar; 54(3):411-8. PubMed ID: 15710992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Which system is better to predict prognosis of patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization as initial therapy? Comparison between CLIP and JIS in a Japanese population.
    Urakawa H; Kora SI; Mitsufuji T; Osame A; Higahsihara H; Yoshimitsu K
    Acta Radiol; 2016 Dec; 57(12):1445-1452. PubMed ID: 26861204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score.
    Kudo M; Chung H; Haji S; Osaki Y; Oka H; Seki T; Kasugai H; Sasaki Y; Matsunaga T
    Hepatology; 2004 Dec; 40(6):1396-405. PubMed ID: 15565571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential prognostic impact of renal insufficiency on patients with hepatocellular carcinoma: a propensity score analysis and staging strategy.
    Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Chiou YY; Lee RC; Lee FY; Huo TI; Lee SD
    J Gastroenterol Hepatol; 2012 Apr; 27(4):690-9. PubMed ID: 22436058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients.
    Chen L; Ni CF; Chen SX; Cao JM; Zhu HD; Guo JH; Zhu GY; Zhong BY; Ding W; He SC; Deng G; Teng GJ
    J Vasc Interv Radiol; 2016 Sep; 27(9):1288-1297. PubMed ID: 27013402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of seven prognostic staging systems in patients who undergo hepatectomy for hepatocellular carcinoma.
    Kondo K; Chijiiwa K; Nagano M; Hiyoshi M; Kai M; Maehara N; Ohuchida J; Nakao H; Ohkuwa Y
    Hepatogastroenterology; 2007; 54(77):1534-8. PubMed ID: 17708292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion.
    Kim KM; Kim JH; Park IS; Ko GY; Yoon HK; Sung KB; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Gastroenterol Hepatol; 2009 May; 24(5):806-14. PubMed ID: 19207681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum microRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Zhan M; Li Y; Hu B; He X; Huang J; Zhao Y; Fu S; Lu L
    J Vasc Interv Radiol; 2014 Aug; 25(8):1279-1287.e1. PubMed ID: 24935355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the prognostic value of Okuda, Cancer of the Liver Italian Program, and Japan Integrated Staging systems for hepatocellular carcinoma patients undergoing radiotherapy.
    Seong J; Shim SJ; Lee IJ; Han KH; Chon CY; Ahn SH
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1037-42. PubMed ID: 17234356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation and ranking of seven staging systems of hepatocellular carcinoma.
    Chen ZH; Hong YF; Lin J; Li X; Wu DH; Wen JY; Chen J; Ruan DY; Lin Q; Dong M; Wei L; Wang TT; Lin ZX; Ma XK; Wu XY; Xu R
    Oncol Lett; 2017 Jul; 14(1):705-714. PubMed ID: 28693224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma.
    Hickey R; Mouli S; Kulik L; Desai K; Thornburg B; Ganger D; Baker T; Abecassis M; Ralph Kallini J; Gabr A; Gates VL; Benson Iii AB; Lewandowski RJ; Salem R
    J Vasc Interv Radiol; 2016 Jun; 27(6):795-802. PubMed ID: 27038686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort.
    Hu HT; Kim JH; Lee LS; Kim KA; Ko GY; Yoon HK; Sung KB; Gwon DI; Shin JH; Song HY
    J Vasc Interv Radiol; 2011 Jul; 22(7):917-23. PubMed ID: 21571545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Cho YK; Chung JW; Kim JK; Ahn YS; Kim MY; Park YO; Kim WT; Byun JH
    Cancer; 2008 Jan; 112(2):352-61. PubMed ID: 18008352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.